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Background: Real world data (RWD) are increasingly used to inform drug reimbursement 
decisions, but it is unclear how well outcomes from real world studies compare to those of 
clinical trials. This systematic review seeks to compare outcomes for sunitinib in routine UK 
clinical practice with the sunitinib registrational and expanded-access program clinical trials.
Method: Systematic review of the real world published literature was undertaken. UK obser-
vational studies recording first- or second-line sunitinib efficacy were included. A qualitative 
summary of the results and comparison to the controlled clinical trials was conducted. Fifteen 
real world studies were included, 14 of which were only available as posters/presentations.
results: Real world study reporting quality was generally low, making comparisons with 
the clinical trials difficult. Practice relating to starting dose, dose modification, timing of 
therapy initiation, and other factors varied between centers. Median progression-free 
survival and adverse events were generally comparable to the clinical trial outcomes, but 
overall survival was not.
conclusion: There are few published data on sunitinib use in UK clinical practice. 
Studies are characterized by lack of peer reviewed publication and heterogeneity in 
design, reporting, and analysis. For use of RWD in the reimbursement setting, data 
collection and reporting will need to improve.
highlights
There are few published data on sunitinib use in UK clinical practice.
Studies are characterized by lack of peer reviewed publication and heterogeneity in 
design, reporting, and analysis.
Practice varies considerably between different UK centers.
Median progression-free survival and adverse events are generally comparable to the 
clinical trial outcomes, but overall survival is not.
For use of real world data in the reimbursement setting, data collection and reporting will 
need to improve.
Keywords: carcinoma, renal cell, clinical practice variations, drug reimbursement, real world data, sunitinib, 
United Kingdom
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introduction
Rising prevalence of, and improving survival from malignancy 
means that cost concerns form an increasingly important con-
sideration in the allocation of healthcare resources. While value 
is increasingly discussed, there is no consensus as to how value 
should be measured as it pertains to new medicines. One key ques-
tion is whether the randomized controlled clinical trial (RCT) pro-
vides the best basis for the assessment of the value that a medicine 
brings in clinical practice. In an attempt to address this, healthcare 
providers are increasingly looking to real world data (RWD) (1). 
While RCTs are the best source of evidence for determining the 
efficacy of a treatment in a specific population, there are perceived 
challenges in generalizing the results of these studies. RWD 
provides an opportunity to supplement evidence from RCTs with 
data relating to the use of the medicine in clinical practice. However, 
the greater susceptibility of RWD to sources of bias means that high 
quality studies are particularly important in providing an accurate 
assessment of how the drug works in clinical practice.
Sunitinib is a small molecule tyrosine kinase inhibitor (TKI) 
identified as a potent inhibitor of both vascular endothelial growth 
factor (VEGF) and platelet-derived growth factor (PDGF) recep-
tors. Sunitinib demonstrated efficacy in the single arm phase 
II trials in cytokine refractory metastatic renal cell carcinoma 
(mRCC) patients (2, 3). From these results, sunitinib gained a 
conditional license for the treatment of mRCC, subsequently 
converted to a full license upon the results of the pivotal phase 
III trial (4).
In addition to the registrational studies, an expanded-access 
program (EAP) was initiated in 2005, at 246 sites in 52 countries 
across the world (5). The program was run to a tightly defined 
protocol, but in a wider range of centers and with less stringent 
entry criteria than the registrational trials. The primary objective 
was to provide sunitinib on a compassionate basis to patients 
with mRCC in countries where marketing authorization had not 
been granted, or who were ineligible for inclusion in the RCT. The 
authors also sought to provide additional understanding of the 
efficacy of sunitinib in patient sub groups less well represented 
in the registrational RCTs, particularly older patients, those with 
poorer performance status or brain metastases.
Clinical experience in mRCC in the UK has been substantial 
and there should therefore be a large evidence base upon which 
to establish the real world performance of sunitinib in the treat-
ment of mRCC. This systematic review aims to identify the data 
pertaining to sunitinib use in UK clinical practice, focusing on 
safety and therapeutic effectiveness, and to compare these data 
to those in the registrational RCTs and the EAP. Quality of the 
reporting of these data will also be assessed.
Materials and Methods
search strategy
All authors were involved in the development of the search strat-
egy. We searched Medline, Medline (R) In-Process, EMBASE, 
EMBASE Daily Alerts, and BIOSIS Pre Reviews through OVID. 
Sunitinib was granted marketing authorization in 2006 and 
therefore studies published between 1 January 2006 and the 25 
September 2013 were considered. We also searched relevant 
congresses; ASCO-Genitourinary, European Society of Medical 
Oncology, European International Kidney Cancer Symposium, 
and National Cancer Research Institute (NCRI), between January 
2006 and September 2013. The complete search string used can be 
found in Table S1 in Supplementary Material. Citation screening 
was performed using Reference Manager 12 (Thomson Reuters). 
Finally, a number of real world studies were known to exist by the 
authors though not published in peer reviewed journals (6–9). 
These were included in the study and are available on request 
from corresponding author Davinder Singh Theti.
All identified citations had their titles and abstracts reviewed 
(if available) on first pass and those not considered relevant were 
excluded. Full papers were obtained for remaining references 
and assessed independently by two researchers. Disputes as to 
eligibility were discussed within the project team and resolved 
by consensus. All papers were reviewed according to the selec-
tion criteria given in Table 1. Reasons for excluding studies were 
documented.
Data extraction
A pre-prepared data extraction table was created in Microsoft® 
Excel. Outcomes extracted included median PFS (mPFS), median 
OS (mOS), PROs, and adverse events (AEs). We prospectively 
identified the following relevant prognostic or predictive factors 
for extraction along with other relevant information: prognostic 
score, age, sex, prior treatment, presence or absence of brain 
metastases, race, and smoking history. Surgical history was 
excluded as surgical resection is no longer considered a robust 
indication of performance status as it was in the pre TKI era. Data 
extraction was conducted independently by two researchers, with 
disputes resolved by consensus.
assessment of Quality
Real world study quality was assessed independently by two 
different researchers. There is no consensus on a specific tool 
for the critical appraisal of real world studies. Real world stud-
ies often lack a control arm, and therefore, the authors selected 
the Chambers tool (10) as it does not penalize studies for this, 
thus reducing bias toward a low study quality. The number and 
pattern of questions answered with a “yes” indicates the quality 
of the study: “Good” = all eight questions answered yes; “satisfac-
tory” = questions 2 and 4–7 answered with “yes”; “poor” if the 
answer is not “yes” to one or more of the questions required for 
a satisfactory rating (see Table S2 in Supplementary Material).
comparison of real World studies to the 
registrational sunitinib rcTs and eaP study
Assessment of the real world studies indicated that it was not 
appropriate for formal statistical analysis and consequently 
a qualitative approach to discussing the results in context of 
the results from the EAP and registrational studies was taken. 
Therefore, any comparisons between the two bodies of evidence 
are restricted to unadjusted, qualitative comparisons.
All real world studies were compared with the trial that 
had the most similar patient population. Studies with a mixed 
treatment population (including both first-line and second-line 
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sunitinib) were compared against the EAP (5), which had no 
restrictive inclusion criteria concerning treatment line. Studies 
with treatment-naive patients were only compared against the 
phase III trial (4) and the treatment-naive subset in the EAP (5).
Two single arm phase II studies were conducted with 
sunitinib. The first study enrolled a total of 63 mRCC patients 
who had failed prior cytokine treatment (3). The second study 
enrolled a total of 106 clear cell mRCC patients who had failed 
prior cytokine treatment (2). Both reported similar outcomes. 
The larger 2007 study only was used for comparison in this 
systematic review. Studies that analyzed prior cytokine patients 
separately were compared against this phase II trial and the 
prior cytokine subset in the EAP. The EAP is used as a com-
parator for all real world studies, as analysis of treatment-naive 
and prior cytokine patients is reported both separately and 
together.
results
In total, 6,910 references were identified. Three thousand four 
hundred three through the OVID database search, 3,486 through 
the search of congresses. Twenty-one records of real world 
sunitinib data were known to the authors prior to searching. A 
summary is provided in the CONSORT flow diagram (Figure 1). 
Of the 3,403 references obtained through OVID, 47 references 
remained after duplicates were removed and first pass review was 
conducted. Thirty-seven were excluded after further examina-
tion of the full text. Of these, 21 were excluded as they were not 
UK studies, 1 was excluded due to inclusion of other adjuvant 
TaBle 1 | inclusion/exclusion criteria used in the systematic review of UK sunitinib real world studies.
criterion inclusion exclusion
Population Adults ≥18 years with RCC classified as Less than 18 years
Advanced Stage I or II
Locally advanced
Stage III 
Metastatic
Stage IV
Stage III/IV
Intervention First-line sunitinib Studies of patients who were not receiving sunitinib as first line or 
post cytokine
Treatment with sunitinib post cytokine Sunitinib dose <25 mg or >75 mg/day
Mixed population with ≤10% treated with non-first-line sunitinib or treated with 
prior anti-angiogenic therapy
Any regimen other than 4 weeks on 2 weeks off
Sunitinib dose of 25–75 mg/day Inclusion of other therapies for the treatment of RCC with sunitinib
4 weeks on 2 weeks off regimen only
Comparator N/A N/A
Outcomes Effectiveness: PFS, OS, objective response rate (ORR), complete response 
(CR), partial response (PR), stable disease (SD), progressive disease (PD), time 
to progression (TTP), death rate (DR)
Studies that do not incorporate efficacy outcomes
If efficacy data presented, then, patient reported outcomes (PROs): FACT-G, 
FKSI, EQ5D
Safety: incidence of all grade adverse events (AEs), incidence of grade 1–4 
AEs
Setting UK Clinical practice Non UK studies
Design Non-RCT Studies not pertaining to clinical practice
Systematic review of non-RCT RCT
Observational studies
therapies for the treatment of RCC with sunitinib, 7 were case 
reports, and 8 lacked efficacy outcomes.
Of the total 3,486 references obtained from congresses, 154 
references remained after first pass review. One hundred forty-
seven references were excluded after further examination of the 
full text. Of these, 141 were excluded as they were not UK studies, 
1 for reporting RCT data, 3 for lacking outcomes of relevance, and 
2 for reporting on a different tumor type.
All 21 previously known references were retained for second 
pass review, at which point 4 references were subsequently 
excluded each for a different reason; data from outside of UK 
clinical practice, lack of efficacy data, case report, and lack of 
sunitinib data. After second pass review, 16 studies remained 
in total. Several hospitals reported data more than once in dif-
ferent formats. All references that recorded duplicate data were 
excluded; 15 studies remained for inclusion in the analysis.
study characteristics
A summary of the key study characteristics of the registrational 
and EAP studies are given in Table 2 (2, 3, 5). Of note is how 
between them, the trials represent cytokine refractory (phase II) 
and treatment-naive (phase III) patients or both (EAP). Between 
them, the clinical trials provide diverse population subsets to 
compare with the real world studies.
Baseline characteristics of the real world studies are given in 
Table  3. The number of patients per study ranged from 14 to 
395. Ten studies included analysis of first line, treatment-naive 
patients (8, 11–15). Two studies included a separate analysis of 
all patients and second line, prior cytokine patients (14, 15). One 
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study analyzed second-line (prior cytokine) patients only (6). Six 
studies included analysis of a mixture of first- and second-line 
treatment (14–19).
Thirteen studies reported PFS or OS data. Despite reporting 
efficacy data, three of these studies were not comparable against 
any of the trials, as they investigated subgroups not represented 
in the registrational or EAP studies, e.g., receiving treatment vs. 
not receiving treatment (18), outcomes by plasma thyroid stimu-
lating hormone levels (7), and Furhman grading (13). Wagstaff 
et al. (19) was not compared as the study was restricted to AEs 
and ORR.
Results 
identified 
through 
OVID: 3403
OVID records after 
duplicates removed 
via RefMan: 1945
OVID
accepted 
for second 
pass: 47
OVID final: 
10
Additional 
results 
identified 
through 
searching 
congresses: 
3486
Additional 
records 
known to 
authors: 21
Congresses
accepted for 
second 
pass: 154
Congresses final: 
7
Records 
known to 
authors
accepted 
for 
second
pass: 21
Records known 
to authors final: 
16
Included RWD studies after duplicates and superseded studies 
removed: 15
Congresses: 3332 
excluded on first 
pass review
OVID
1898 excluded on 
first pass review
Congresses 
147 excluded on 
second pass review 
OVID  
37 excluded on 
second pass review
Records known to 
authors 4 excluded 
on second pass 
review
FigUre 1 | cOnsOrT study flow diagram for the identification and selection of studies for this systematic review.
Quality assessment
Methodological quality was rated as poor according to the 
Chambers tool for all real world studies. Most studies were 
recorded in poster or abstract form and so lacked sufficient detail 
to score yes to all questions. The full quality assessment for each 
study is given in Table S2 in Supplementary Material.
comparison of mPFs and mOs of real World 
studies With the registrational and eaP studies
Results for mPFS and mOS from the real world studies are 
summarized in Table  4, along with unadjusted comparisons 
TaBle 3 | Baseline characteristics of patients in the sunitinib real world studies and registrational/eaP studies used as comparators in this systematic 
review.
study Patient no. Prognostic score or Ps Brain metastases  
(%)
age as given (range if given) sex  
(% male)
Motzer et al. (2), 
phase II
106 MSKCC: F = 57.5%, I = 38.7%, P = 3.8% 0.0 Median 56 years (32–79) M 63 
Motzer et al. (4), 
phase III
750 MSKCC: F = 38%, I = 56%, P = 6%, PS: 
0 = 62%, 1 = 38% 
0.0 Median 62 years (27–87) M 71 
Gore et al. (5), EAP 4564 MSKCC: F = 36%, I = 44%, P = 9%, 
NR = 11%, PS: 0 = 42%, 1 = 43%, 
2 = 12%, 3 = 2%, 4 <1%
7.0 Median 59 years (19–89) M 74 
Coward et al. (20) 62 NR NR ≤70, 61%; ≥70, 39% NR
Fisher et al. (15) 62 TN = 39, 
PT = 18
MSKCC: F = 62.5%, I = 35.9%, P = 1.6% NR Median 57 years M 75
Galvis et al. (14) 395 TN = 262 
PT = 133
PS: 0–1 = 81%, >1 = 19% NR ≤60 years = 30%; 
61–70 years = 42%; 
≥70 years = 28%
M 66
Goranova et al. (17) 129 PS: 0 = 33%, 1 = 51%, 2 = 16% NR Median 63 years (21–87) M 67
Liberatoscioli et al. (6) 31 MSKCC: F = 61.3%, I = 25.8%, 
P = 12.3%; PS: 0 = 32.3%, 1 = 38.7%, 
2 = 25.8%, 3 = 3.2%
6.5% Median 58 years (38–71) M 74.3
Maclennan et al. (12) 87 PS: 0 = 22%, 1 = 59%, 2 = 18% 16.0% Median 58 years (39–78) M 72
MacLeod et al. (11) 73 PS: 0 = 18%, 1 = 18%, 2 = 5%, NR = 59% NR Median 62 M 74
Miscoria et al. (16) 141 Heng: F = 19.9%, I = 53.2%, P = 26.9%; 
PS: 0–1 = 78.7%, 2–3 = 21.3%
NR Median 61 (33–86) M 75
Mullard et al. (21) 42 Heng: F = 43%, I = 38%, P = 19% PS: 
0–1 = 91%
NR Median 61 years (43% >65 years) NR
Sparrow (9) 14 PS: 0 = 28%, 1 = 72% 0.0 Median 65 years (53–80) M 64
Susnerwala (8) 35 PS: 0 = 3%, 1 = 80%, 2 = 14%, NR = 3% 0.0 NR M 60
NR, not recorded; TN, treatment naïve; PT, pre-treated. MSKCC, Memorial Sloane Kettering Cancer Centre. F, favorable; I, intermediate; P, poor. Studies by James et al. (18), Sim 
and Hayward (7), Visvardis et al. (13), and Wagstaff et al. (19) were omitted from this table as they could not be compared directly to the registrational studies or EAP.
TaBle 2 | summary of the sunitinib registrational and eaP studies used as comparators in this systematic review.
study Patient no. study design reported outcomes
Motzer et al. 
(2), Phase II
106 Single arm trial of sunitinib in second-line cytokine refractory 
patients
Endpoints: primary – ORR, secondary – TTP, PFS, OS, duration 
of response
Motzer et al. 
(4), phase III
750 Randomized, controlled study of sunitinib vs. interferon alpha in 
treatment-naive patients
Endpoints: primary – PFS, secondary – ORR, OS, safety
Gore et al. (5), 
EAP
4564 Observational study of sunitinib in trial ineligible mRCC patients in 
countries without licensed access. Population included first and 
second line patients
PFS, OS, ORR in the subgroups: over 65, ECOG PS ≥2, brain 
metastases, prior cytokine treatment, non-clear cell histology. 
Safety evaluated in all patients
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against the clinical trial of most relevance. The phase II study 
(2) reported mPFS of 8.8 months (95% CI 7.8–13.5) and mOS 
of 23.9  months (95% CI 14.1–30.7). The phase III registration 
study (4) reported mPFS of 11 months with sunitinib (95% CI 
11.0–13.0) compared with mPFS of 5  months with interferon 
(IFN) alpha (95% CI 4.0–6.0). Median OS was 26.4 months in the 
sunitinib arm (95% CI 23.0–32.9) compared with 21.8 months in 
the IFN-alpha arm (95% CI 17.9–26.9). The EAP (5) reported a 
similar mPFS of 10.9 months (95% CI 10.3–11.2) for all patients 
(10.8  months in patients with prior cytokine treatment and 
11.1 months in treatment-naive patients). Median OS was lower 
in the EAP than in the phase III registration study, at 18.4 months 
(95% CI 17.4–19.2) for all patients (18.4 months in patients with 
prior cytokine treatment and 18.1  months in treatment-naive 
patients).
Five real world studies analyzed a mixed patient popula-
tion [first-line and prior cytokine; (14, 16–19)]. Of these, only 
three studies reported mPFS and mOS. In each of these studies, 
mPFS was similar to that reported in the EAP for all patients, at 
10 months (17), 11 months (14), and 10.8 months (16). Median 
OS was also similar, at 17  months (17), 18  months (14), and 
18.4 months (16).
Of the eight real world studies that included treatment-naive 
patients only, all included some PFS or OS analysis (7–9, 11–13, 
20, 21), but only two reported mPFS suitable for comparison. 
The mPFS in these two studies was similar to that reported in 
the phase III study and EAP, at 8.9 months (12) and 9 months 
(8). Seven studies reported mOS suitable for comparison, which 
varied widely, ranging from 10 months (21) to 23 months (20).
Of the three studies that analyzed therapeutic effectiveness in 
cytokine refractory patients (6, 14, 15), two reported on mPFS (6, 
15). Both reported a similar mPFS compared to the comparative 
trials (phase II and EAP) at 9 months (15) and 10.9 months (6). 
All three studies reported on mOS, two of which were lower in the 
TaBle 4 | comparison of real world studies compared to relevant registrational and eaP studies.
Median PFs in months Median Os in months
study (N = population)
real world study comparator study real world study comparator study
Coward et al. (20) (N = 62), treatment-naive 
population
NR NA 23 Phase III 26.4 EAP-TN 18.1
Fisher et al. (15) (N = 18), pre-treated population 6.7 (95% CI 0.7–12.7) Phase II 8.8 EAP-PT 10.8 37.6 (95% CI 2.6–72.5) Phase II 23.9 EAP-PT 18.4
Fisher et al. (15) (N = 39), treatment-naive 
population
9 (95% CI 8.1–9.9) Phase III 11.0 EAP-TN 11.1 17.4 (95% CI 11.6–23.2) Phase III 26.4 EAP-TN 18.1
Galvis et al. (14) (N = 395), mixed population 11.0 EAP-M 10.9 18.0 EAP-M 18.4
Galvis et al. (14) (N = 133), pre-treated population NR NA 20.5 Phase II 23.9 EAP-PT 18.4
Galvis et al. (14) (N = 262), treatment-naive 
population
NR NA 18.6 Phase III 26.4 EAP-TN 18.1
Goranova et al. (17) (N = 129), mixed population 10 EAP-M 10.9 17.0 EAP-M 18.4
Liberatoscioli et al. (6) (N = 31), pre-treatment 
population
10.9 Phase II 8.8 EAP-PT 10.8 26.3 Phase II 23.9 EAP-PT 18.4
Maclennan et al. (12) (N = 87), treatment-naive 
population
8.9 Phase III 11 EAP-TN 11.1 14.7 Phase II 23.9 EAP-PT 18.4
MacLeod et al. (11) (N = 73), treatment-naive 
population
NR NA 14.4 Phase II 26.4 EAP-TN 18.1
Miscoria et al. (16) (N = 141), mixed population 10.8 EAP-M 10.9 18.4 EAP-M 18.4
Mullard et al. (21) (N = 42), treatment-naive 
population
NR NA 10.0 Phase III 26.4 EAP-TN 18.1
Sparrow (9) (N = 14), mixed population 9.0 (95% CI 8.1–10.0) EAP-M 10.9 25.2 (95% CI 8.0–42.2) EAP-M 18.4
Sparrow (9) (N = 9), treatment-naive population NR NA 10.5 (range 3–32) Phase III 26.4 EAP-TN 18.1
Susnerwala (8) (N = 34), treatment-naive population 9.0 Phase III 11.0 EAP-TN 11.1 20.0 Phase III 26.4 EAP-TN 18.1
EAP-M, EAP mixed population; EAP-T N, EAP treatment naïve population. EAP-PT, EAP pre-treated population; NR, not recorded; NA, not applicable. Studies by James et al. (18); 
Sim and Hayward (7), Visvardis et al. (13), and Wagstaff et al. (19) were omitted from this table as they could not be compared directly to the registrational studies or EAP.
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real world setting compared to the phase II study, at 17.4 months 
(15) and 20.5 months (14).
safety
Relative to the registrational studies and EAP, no new AEs were 
reported in any of the real world studies.
Outcomes related to sunitinib access
One study (18) investigated the effect of access to first-line 
treatment (sunitinib or sorafenib) on OS. Prior to approval by 
NICE, access for sunitinib and sorafenib was determined by 
local funding decisions and resulted in variable access across 
England and Wales. James et  al.’s data showed that patients 
who received treatment with sunitinib or sorafenib compared 
to those who did not had a longer OS (hazard ratio =  0.46, 
95% CI 0.21–1.01, p =  0.05). The OS advantage was similar 
between patients receiving sunitinib (hazard ratio = 0.49, 95% 
CI 0.18–1.36, p = 0.17) or sorafenib (hazard ratio = 0.44, 95% 
CI 0.11–1.69, p = 0.21).
comparison of Treatment center on Outcomes
Goranova et al. (17) was the only study to compare mPFS and 
mOS between two cancer centers [Northern Centre for Cancer 
Care (NCCC) and James Cook University Hospital (JCUH)]. 
Along with outcome data, the study compared variables at these 
two centers including dose reduction at outset, WHO PS, and 
dose delay of 4 weeks or more. mPFS was longer among patients 
treated at NCCC compared with JCUH (12 and 6 months, respec-
tively). Median OS was also higher at NCCC compared with 
JCUH, with NCCC documenting mOS of 23 months compared 
to 14 months at JCUH. The distribution of patients by PS was 
similar between the two centers, and no other comparative infor-
mation on baseline characteristics was provided. Both initiation 
of treatment at reduced dose and use of treatment breaks differed 
between the centers. NCCC started fewer patients on a reduced 
dose (six patients) compared with JCUH (22 patients). Similarly, 
NCCC delayed dose in fewer patients than JCUH (8 and 19 
patients, respectively). Patients who had undergone treatment 
delay experienced significantly better mPFS and numerically 
better mOS than those who did not (mPFS: 17 vs. 6  months, 
respectively, p = 0.0265 and mOS: 23 vs. 14 months, respectively, 
p = 0.0705).
Discussion
There are very few published reports of sunitinib real world use 
in the UK. Of the studies, which have been conducted, only 
two were published in full text peer reviewed journals at the 
time of performing this study, the majority appearing in abstract 
form. The majority of studies achieved a score of “poor” on 
the Chambers quality assessment tool, mainly through lack of 
reporting of basic methodological detail. None of the studies 
reported loss to follow up or described the methodology used 
for defining progression or response and it is unclear whether 
RECIST criteria was appropriately applied and whether 
response was investigator assessed by blinded radiological 
review or determined in some other way. Several of the stud-
ies were designed to answer quite specific questions and had 
selected patient groups. There was extensive heterogeneity in 
the patients treated and in the clinical practices described, 
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making it difficult to extrapolate the results of these studies to a 
wider patient group.
Therapeutic effectiveness in the real World
The data, which have been published, and notwithstanding 
the caveats described above regarding interpretation of those 
data, suggest that sunitinib is performing comparably in the 
real world setting to the registrational and EAP studies with 
regards to PFS. mPFS of treatment-naive patients in the real 
world was consistently similar to that reported in the phase III 
trial (despite including patients of a poorer prognosis) and EAP. 
The impact on OS was more interesting. Of the treatment-naive 
population, the lowest mOS reported was 10  months (21), 
lower than the mPFS recorded in the phase III trial or EAP. In 
contrast, Coward et al. (20) reported mOS of 23 months, similar 
to that seen in the phase III study, and greater than reported 
in the EAP. Furthermore, given the strict inclusion criteria in 
the phase III trial (ECOG PS 0–1 only) compared with the real 
world studies (the majority included a considerable proportion 
of patients of PS ≥2; see Table 4) and the association between 
poor PS and poorer outcome, these results demonstrate that the 
efficacy reported in the pivotal trial can be reproduced in clinical 
practice.
Why the OS was not more consistently reproduced in the 
real world when PFS is, is not clear. Assuming that the data are 
accurate, it implies a shorter time from progression to death 
in some centers than in others or the registrational studies 
and EAP. There are a number of possibilities, which include 
definition of progression being different from that used in 
clinical trials (and so reported PFS being artificially longer 
in the RWD studies), patients being sicker at progression, or 
perhaps poorer access to second-line treatment options (such 
as funded second-line treatments or clinical trials) than in the 
registrational studies.
In the phase III study, 56% of the sunitinib patients received 
post-study treatment (4). Only two of the real world studies 
reported proportion of patients that received second-line treat-
ment and both studies reported much lower proportions than in 
the phase III study (Susnerwala – 20% and Mullard et al. – 12%). 
In the UK, between 2007 and 2008, only 2.3% of renal cancer 
patients were entered into clinical trials of all types; both localized 
and metastatic (22) annual report and most of the RWD recorded 
in the current study pertains to patients treated at a time when 
no funded second-line agents were available in the UK. This is 
therefore a plausible reason for the consistently lower mOS in the 
real world studies compared to the phase III study. Unfortunately, 
most of the studies lacked sufficient reporting of baseline patient 
characteristics and of subsequent treatments given to allow us to 
reach a conclusion.
Treatment heterogeneity Between centers
Dose intensity is an important determinant of therapeutic effect. 
Goranova et al. (17) reported that patients who were started on 
a lower dose of sunitinib had lower mPFS than those who were 
started at 50  mg, the recommended starting dose. That study 
reported patients from two centers where, despite broadly 
similar patient demographics and close geographical proximity, 
starting at lower dose was more prevalent in one center that also 
reported poorer outcomes. Higher plasma exposure to sunitinib 
has been shown to be associated with longer TTP and mOS 
compared with lower exposure (23). This implies that some of 
these patients who were started at a lower dose were not receiv-
ing optimal exposure. The authors also question whether they 
could achieve better results, and highlight initiation dose and 
willingness to dose escalate to find the optimal treatment dose as 
two areas that could be further optimized; implicitly to lessen the 
variation in outcome for patients between these geographically 
close centers.
Use of real World Data to inform Drug 
reimbursement
Real world data are increasingly being called upon to guide clini-
cal practice and to help payers refine their assessment of “value.” 
The growing importance of RWD has led to the establishment of 
novel initiatives, such as the UK’s systemic anti-cancer therapy 
(SACT) dataset and linkage to other databases, such as the 
National Cancer Registration Service (NCRS) database. This, in 
part, is the consequence of a recognized unmet need for quality 
RWD that can be accessed as an aid to making well-informed 
funding decisions and improving service provision where 
necessary. NHS England’s “commissioning through evaluation” 
program provides a framework to make available specialized 
treatments, which are not routinely available due to inadequate 
evidence of clinical or cost effectiveness. Data will be collected 
prospectively with a view to informing the decision regarding 
routine commissioning (24). The national Cancer Drugs Fund 
in England may also adopt this approach. The UK Department 
of Health has suggested that the collected RWD will be used to 
negotiate pricing discounts with pharmaceutical companies (25). 
These uses of RWD may prove controversial. Reimbursement 
decisions in particular require robust, high quality comparative 
data, which provide some indication as to the relative effect of new 
vs. established treatments. An RCT provides such comparative 
evidence, but a single arm real world study, or even prospective 
collection of data on the effectiveness of a new medicine in the 
real world, does not.
End points used in clinical trials may be impractical in the 
real world setting. In oncology in particular, PFS is commonly 
used as the primary end point for registrational purposes, but 
PFS will not be collected under the NCRS. Less rigorous scanning 
requirements in the real world may make any comparisons less 
meaningful. It is likely that these reimbursement decisions will 
rely on OS as an end point.
As we can see from this review, in small data sets, PFS was 
fairly reproducible but OS was not. Had this systematic review 
assessed OS alone, it would have been difficult to conclude 
anything other than that sunitinib was not performing as well 
in the real world, but real world PFS data in this review refute 
that. If anything, it would appear that a combination of a lack 
of subsequent treatment options and perhaps slightly poorer 
patient prognostic characteristics are to blame for the lower 
survival, although this latter point is difficult to state definitively 
as patient characteristics were often not adequately described in 
the included analyses.
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summary
Real world data will increasingly be used to guide reimbursement 
decisions, but the interpretation of those data is difficult due 
to often inadequately described methodology and substantial 
heterogeneity in clinical practice. While PFS in the treatment-
naive populations from real world studies was consistent with 
the phase III trial, OS varied considerably. The variability in OS 
could be due to a number of factors, including access to second-
line treatment or other differences in clinical practice or patient 
demographic features. Unfortunately, the reported real world 
studies were insufficiently detailed to allow further explora-
tion of the reasons underpinning this heterogeneity, but do 
raise significant concerns that health technology assessments 
underpinned by naive comparisons of RWD OS vs. survival 
in clinical trials could be heavily biased. These problems often 
exist with published observational data and the impact that 
poor reporting has on usability is well known. An agreed set of 
reporting criteria have been produced [the STROBE statement; 
von Elm et al. (26)] to provide further guidance on optimizing 
reporting of observational data. This review highlights the need 
for authors to adhere to this, especially when presenting find-
ings in posters or abstracts. Whole system wide data registries, 
such as those proposed in the UK, could be a powerful tool 
and may go some way to ensuring comparable populations 
and reducing heterogeneity. That said, some heterogeneity of 
patient features and clinical practice will be inevitable and it 
is critical, for these databases to be of use, that comprehensive 
data are captured on individuals, incorporating outcomes from 
the whole treatment path from diagnosis to cure or death. Only 
in this way will investigators seeking to make assessments of 
the relative effectiveness of medicines have the tools to do so.
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